Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer

BJU International

Volumn 101, Issue 11, 2008, Pages 1347-1355

  Hadaschik, Boris A ^a,b   Ter Borg, Melanie G ^a,b   Jackson, John ^b   Sowery, Richard D ^a,b   So, Alan I ^a,b   Burt, Helen M ^b   Gleave, Martin E ^a,b,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Department of Urologic Sciences ^*  (Canada)

Author keywords

Bladder cancer; Cisplatin; Intravesical therapy; Orthotopic mouse model; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MASS SPECTROMETRY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; FEMALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PACLITAXEL; URINARY BLADDER NEOPLASMS;

EID: 43049144302     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07571.x     Document Type: Article

References (37)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 : 4 34
2. Clark PE. Bladder cancer. Curr Opin Oncol 2007 19 : 241 7
3. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol 2007 4 : 254 60
4. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997 158 : 62 7
5. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003 169 : 96 100
6. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991 51 : 4347 54
7. Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991 51 : 5144 52
8. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 1994 152 : 374 8
9. Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997 40 : 285 92
10. Okeke AA, Probert JL, Gillatt DA, Schwaibold H. Is intravesical chemotherapy for superficial bladder cancer still justified? BJU Int 2005 96 : 763 7
11. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release 2002 78 : 81 95
12. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995 153 : 1444 50
13. Sylvester RJMA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002 168 : 1964 70
14. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006 67 : 1216 23
15. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002 20 : 158 66
16. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005 174 : 14 20
17. Nativ O, Aronson M, Medalia O et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 1997 70 : 297 301
18. Au JL, Kalns J, Gan Y, Wientjes MG. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 1997 41 : 69 74
19. McKiernan JM, Masson P, Murphy AM et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006 24 : 3075 80
20. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of paclitaxel. Int J Pharm 1996 132 : 195 206
21. Hadaschik BA, Black PC, Sea JC et al. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int 2007 100 : 1377 84
22. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006 98 : 1806 18
23. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 2001 296 : 1035 42
24. Uchino H, Matsumura Y, Negishi T et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005 93 : 678 87
25. Sato K, Yuasa T, Nogawa M et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006 95 : 1354 61
26. Pu YS, Chen J, Huang CY, Guan JY, Lu SH, Hour TC. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol 2001 165 : 2082 5
27. Kugler A, Haschemi R, Zoller G, Gross AJ, Kallerhoff M, Ringert RH. In vitro investigations of new therapeutic agents on bladder tumor cell lines. Urol Res 1997 25 : 247 50
28. Havaleshko DM, Cho H, Conaway M et al. Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 2007 6 : 578 86
29. Fraser MO, Lavelle JP, Sacks MS, Chancellor MB. The future of bladder control-intravesical drug delivery, a pinch of pepper, and gene therapy. Rev Urol 2002 4 : 1 11
30. Tyagi P, Tyagi S, Kaufman J, Huang L, de Miguel F. Local drug delivery to bladder using technology innovations. Urol Clin North Am 2006 33 : 519 30
31. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 2002 20 : 3185 6
32. Gao X, Au JL, Badalament RA, Wientjes MG. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 1998 4 : 139 43
33. Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999 44 : 241 8
34. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004 10 : 7677 84
35. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999 59 : 3512 7
36. Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet 1983 1 : 1378 9
37. Bouffioux C, Denis L, Oosterlinck W et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 1992 148 : 297 301